

# Brian J Davis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6361606/publications.pdf>

Version: 2024-02-01

126  
papers

6,052  
citations

100601

38  
h-index

87275

74  
g-index

126  
all docs

126  
docs citations

126  
times ranked

7199  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
2	The ABR 2021 Radiation Oncology Remote Examinations: Development, Administration, and Implications for the Future. <i>Journal of the American College of Radiology</i> , 2022, , .	0.9	0
3	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	0.9	140
4	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 174-185.	0.4	77
5	Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 514-523.	2.0	10
6	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 953-963.	0.4	6
7	<sup>11</sup> C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen $\geq 0.1$ ng/ml. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 358.	0.3	8
8	Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT). <i>Current Opinion in Urology</i> , 2021, 31, 199-205.	0.9	2
9	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
10	A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1082-1089.	0.4	19
11	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
12	The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 161, 9-15.	0.3	6
13	Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. <i>Practical Radiation Oncology</i> , 2021, 11, e468-e476.	1.1	2
14	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. <i>Brachytherapy</i> , 2021, 20, 1114-1129.	0.2	26
15	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup> C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6376-6383.	3.2	21
16	In response to Dover et al.. <i>Practical Radiation Oncology</i> , 2021, , .	1.1	0
17	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
18	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49

#	ARTICLE	IF	CITATIONS
19	Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 7925-7934.	1.3	6
20	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. <i>Practical Radiation Oncology</i> , 2020, 10, e378-e387.	1.1	1
21	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2019, 140, 68-75.	0.3	20
22	The American Board of Radiology Initial Certification in Radiation Oncology: Moving Forward Through Collaboration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 21-23.	0.4	11
23	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. <i>Advances in Radiation Oncology</i> , 2019, 4, 314-322.	0.6	9
24	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. <i>Advances in Radiation Oncology</i> , 2019, 4, 79-89.	0.6	2
25	Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. <i>Brachytherapy</i> , 2019, 18, 306-312.	0.2	12
26	Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e536-e540.	0.9	6
27	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 229-240.	0.4	24
28	Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. <i>Brachytherapy</i> , 2019, 18, 1-7.	0.2	19
29	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using <sup>11</sup> C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2018, 199, 726-733.	0.2	13
30	Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. <i>Practical Radiation Oncology</i> , 2018, 8, 28-39.	1.1	140
31	ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. <i>Journal of the American College of Radiology</i> , 2018, 15, S132-S149.	0.9	20
32	Low dose rate prostate brachytherapy. <i>Translational Andrology and Urology</i> , 2018, 7, 341-356.	0.6	30
33	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.	0.3	39
34	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. <i>Bladder</i> , 2018, 5, e34.	0.6	2
35	Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? <i>Eur Urol</i> 2017;71:349-50. <i>European Urology</i> , 2017, 71, 351-352.	0.9	0
36	Brachytherapy in the Management of Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 491-513.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Sternum First, Perhaps Pelvis Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 496.	0.4	0
38	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Advances in Radiation Oncology, 2017, 2, 437-454.	0.6	21
39	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy, 2017, 16, 266-276.	0.2	26
40	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	1.9	106
41	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535.	0.4	35
42	Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with <sup>11</sup> C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2017, 197, 129-134.	0.2	45
43	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348.	0.9	51
44	Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil. Practical Radiation Oncology, 2017, 7, 42-49.	1.1	17
45	ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Advances in Radiation Oncology, 2017, 2, 62-84.	0.6	30
46	Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. Journal of Contemporary Brachytherapy, 2016, 5, 371-378.	0.4	5
47	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
48	Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 3864-3871.	0.8	177
49	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncology, The, 2016, 17, 1435-1444.	5.1	107
50	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Practical Radiation Oncology, 2016, 6, e117-e126.	1.1	26
51	Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. European Urology, 2016, 69, 135-142.	0.9	58
52	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research, 2015, 75, 4688-4696.	0.4	105
53	Feasibility of vibroacoustography with a quasi-2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: A pilot <i>ex vivo</i> study. Medical Physics, 2014, 41, 092902.	1.6	4
54	ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 278-288.	0.6	13

#	ARTICLE	IF	CITATIONS
55	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminomaâ€”The Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 24.e1-24.e6.	0.8	12
56	Shape analysis of the prostate: Establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance. <i>Brachytherapy</i> , 2014, 13, 465-470.	0.2	2
57	Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus $\alpha$ -X $\alpha$ ™. <i>Radiation Oncology</i> , 2014, 9, 171.	1.2	5
58	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2014, 13, 27-31.	0.2	24
59	Late gastrointestinal morbidity in patients with stage II testicular seminoma treated with radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 496-500.	0.8	9
60	Response to Drs Rogers, Hayes, and Demanes. <i>Brachytherapy</i> , 2014, 13, 523-525.	0.2	0
61	Magnetic Resonance Imaging-guided Cryoablation of Recurrent Prostate Cancer After Radical Prostatectomy: Initial Single Institution Experience. <i>Urology</i> , 2013, 82, 870-875.	0.5	56
62	Long-term outcomes of radiotherapy for stage II testicular seminomaâ€”the Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1832-1838.	0.8	20
63	Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 822-828.	0.4	161
64	Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline. <i>Journal of Urology</i> , 2013, 190, 441-449.	0.2	368
65	Application of vibro-acoustography in prostate tissue imaging. <i>Medical Physics</i> , 2013, 40, 022902.	1.6	14
66	Vibro-acoustography with 1.75D ultrasound array transducer for detection and localization of permanent prostate brachytherapy seeds:ex vivostudy. , 2013, , .		3
67	Multimodality Therapy Including Surgical Resection and Intraoperative Electron Radiotherapy for Recurrent or Advanced Primary Carcinoma of the Urinary Bladder or Ureter. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 596-600.	0.6	7
68	PSA screening in men newly diagnosed with colorectal cancer: each according to his group's means?. <i>Oncology</i> , 2013, 27, 1038, 1040.	0.4	0
69	Progress in Gene Therapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 172.	1.3	34
70	Long-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1938-1943.	0.4	20
71	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. <i>Brachytherapy</i> , 2012, 11, 6-19.	0.2	399
72	The Relationship of the Intensity of Posttreatment Prostate-Specific Antigen Surveillance and Prostate Cancer Outcomes: Results From a Population-Based Cohort. <i>Mayo Clinic Proceedings</i> , 2012, 87, 540-547.	1.4	4

#	ARTICLE	IF	CITATIONS
73	A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. <i>Brachytherapy</i> , 2012, 11, 299-305.	0.2	35
74	Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. <i>Frontiers in Oncology</i> , 2012, 2, 215.	1.3	107
75	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1061-1065.	0.4	59
76	Treatment of localised prostate cancer with radiation therapy: evidence versus opinion. <i>Clinical and Translational Oncology</i> , 2010, 12, 315-317.	1.2	1
77	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score $\leq 10$ Prostate Cancer Treated With Permanent Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 341-346.	0.4	126
78	Planning Target Margin Calculations for Prostate Radiotherapy Based on Intrafraction and Interfraction Motion Using Four Localization Methods. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 289-295.	0.4	148
79	In Reply to Drs. Oton and Oton. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 962-963.	0.4	0
80	Prostate Cryotherapy Monitoring Using Vibroacoustography: Preliminary Results of an <i>Ex Vivo</i> Study and Technical Feasibility. <i>IEEE Transactions on Biomedical Engineering</i> , 2008, 55, 2584-2592.	2.5	44
81	Estimated limits of IMRT dose escalation using varied planning target volume margins. <i>Physics in Medicine and Biology</i> , 2008, 53, 3777-3788.	1.6	11
82	A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy. <i>PLoS ONE</i> , 2008, 3, e2318.	1.1	160
83	Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry. <i>Physics in Medicine and Biology</i> , 2007, 52, 3105-3119.	1.6	28
84	Prostate brachytherapy seed reconstruction using an adaptive grouping technique. <i>Medical Physics</i> , 2007, 34, 2975-2984.	1.6	9
85	LC-MS/MS Quantification of Zn $\pm 2$ Glycoprotein: A Potential Serum Biomarker for Prostate Cancer. <i>Clinical Chemistry</i> , 2007, 53, 673-678.	1.5	123
86	Treatment of Prostate Cancer Local Recurrence After Radical Retropubic Prostatectomy with 17-Gauge Interstitial Transperineal Cryoablation: Initial Experience. <i>Urology</i> , 2007, 70, 80-85.	0.5	28
87	Seed localization and TRUS-fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. <i>Computer Aided Surgery</i> , 2007, 12, 25-34.	1.8	29
88	Prediction of Radial Distance of Extraprostatic Extension From Pretherapy Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 411-418.	0.4	18
89	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1472-1477.	0.4	92
90	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. <i>Brachytherapy</i> , 2007, 6, 2-8.	0.2	47

#	ARTICLE	IF	CITATIONS
91	Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. <i>Journal of Urology</i> , 2006, 176, 2020-2024.	0.2	73
92	Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. <i>Urology</i> , 2006, 68, 810-814.	0.5	10
93	Seed based registration for intraoperative brachytherapy dosimetry: a comparison of methods. , 2006, , .		0
94	Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. <i>BJU International</i> , 2006, 98, 773-776.	1.3	5
95	TRUS-fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. <i>Studies in Health Technology and Informatics</i> , 2006, 119, 532-7.	0.2	4
96	LETTER TO THE EDITOR. <i>Cancer Journal (Sudbury, Mass )</i> , 2005, 11, 432.	1.0	0
97	A Preclinical Large Animal Model of Adenovirus-Mediated Expression of the Sodium Iodide Symporter for Radioiodide Imaging and Therapy of Locally Recurrent Prostate Cancer. <i>Molecular Therapy</i> , 2005, 12, 835-841.	3.7	62
98	URINARY FISTULAS FOLLOWING EXTERNAL RADIATION OR PERMANENT BRACHYTHERAPY FOR THE TREATMENT OF PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 173, 1953-1957.	0.2	145
99	Examination of dosimetry accuracy as a function of seed detection rate in permanent prostate brachytherapy. <i>Medical Physics</i> , 2005, 32, 3049-3056.	1.6	27
100	Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 419-425.	0.4	325
101	Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 767-776.	0.4	23
102	Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm. <i>Brachytherapy</i> , 2004, 3, 106-112.	0.2	4
103	Morbidity After Brachytherapy for Prostate Adenocarcinoma. <i>Mayo Clinic Proceedings</i> , 2004, 79, 946-947.	1.4	1
104	Prostate brachytherapy seed localization by analysis of multiple projections: Identifying and addressing the seed overlap problem. <i>Medical Physics</i> , 2004, 31, 1277-1287.	1.6	62
105	A method for size estimation for small objects and its application in brachytherapy seed identification. , 2004, , .		0
106	Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression. <i>Cancer Journal (Sudbury, Mass )</i> , 2004, 10, 343-348.	1.0	19
107	Fluoroscopy to ultrasound image registration using implanted seeds as fiducials during permanent prostate brachytherapy. , 2004, , .		10
108	3D visualization, analysis, and treatment of the prostate using trans-urethral ultrasound. <i>Computerized Medical Imaging and Graphics</i> , 2003, 27, 339-349.	3.5	30

#	ARTICLE	IF	CITATIONS
109	Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1131-1140.	0.4	85
110	Measurement of the ultrasound backscatter signal from three seed types as a function of incidence angle: Application to permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1174-1182.	0.4	20
111	Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy, 2003, 2, 98-102.	0.2	13
112	Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Current Opinion in Urology, 2003, 13, 117-122.	0.9	17
113	Brachytherapy Seed Localization from Fluoroscopic Images Using a Statistical Classifier. Lecture Notes in Computer Science, 2003, , 945-946.	1.0	4
114	Prostate Brachytherapy Seed Migration To A Coronary Artery Found During Angiography. Journal of Urology, 2002, 168, 1103-1103.	0.2	51
115	The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer, 2002, 95, 513-519.	2.0	12
116	Metastatic prostate carcinoma to bone. Cancer, 2002, 95, 1028-1036.	2.0	122
117	Electronic and film portal images: a comparison of landmark visibility and review accuracy. International Journal of Radiation Oncology Biology Physics, 2002, 54, 584-591.	0.4	42
118	Prostate brachytherapy seed migration to a coronary artery found during angiography. Journal of Urology, 2002, 168, 1103.	0.2	8
119	<title>Transurethral ultrasound of the prostate for applications in prostate brachytherapy: analysis of phantom and in-vivo data</title>. , 2001, , .		3
120	Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology, 2000, 56, 726-729.	0.5	45
121	PROSTATE BRACHYOTHERAPY SEED MIGRATION TO THE RIGHT VENTRICLE FOUND AT AUTOPSY FOLLOWING ACUTE CARDIAC DYSRHYTHMIA. Journal of Urology, 2000, 164, 1661-1661.	0.2	57
122	178 Supplemental implantation for suboptimal permanent prostate brachytherapy: A prostate phantom study. Radiotherapy and Oncology, 2000, 55, 91-92.	0.3	4
123	Telemedicine in radiotherapy treatment planning: requirements and applications. Radiotherapy and Oncology, 2000, 54, 255-259.	0.3	48
124	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630-2637.		134
125	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630.		34
126	External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. International Journal of Radiation Oncology Biology Physics, 1997, 37, 753-759.	0.4	183